Gilead Sciences Recall Veklury for Injection 100 mg/Vial

Gilead Sciences recently announced a voluntary recall of one lot of its Veklury (remdesivir) for injection 100 mg/vial, to the consumer level, after confirming the presence of a glass particle in the vial during a company investigation.

The Veklury for injection 100 mg/vial is packaged in single dose clear glass vials in powder form and is indicated for the treatment of COVID-19 in adults and pediatric patients that are either hospitalized or not hospitalized but have mild-to-moderate COVID-19 and are at high risk for progression to severe virus, including hospitalization or death.

Recalling its lyophilized form, the lot affected — No. 47035CFA — was found to potentially contain glass particles after the company received a customer complaint and then confirmed a particle in said vial.

Administering an injectable project that contains glass particles could result in local irritation or swelling in response to foreign material. Additionally, the particulate can travel through the blood vessels to various organs and block blood vessels to the heart, lungs, or brain, causing stroke or death. Currently, Gilead has received no reports of adverse events related to the recall.

Gilead is recommending that customers stop using the affected lot and return the vials to the company.